Items where authors include "Lazarus, R"

Article

Hardt, K, Vandebosch, A, Sadoff, J et al. (285 more authors) (2022) Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2) : results of a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Infectious Diseases, 22 (12). pp. 1703-1715. ISSN 1473-3099

Flaxman, A, Marchevsky, NG, Jenkin, D et al. (184 more authors) (2021) Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). The Lancet, 398 (10304). pp. 981-990. ISSN 0140-6736

Emary, KRW, Golubchik, T, Aley, PK et al. (64 more authors) (2021) Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7) : an exploratory analysis of a randomised controlled trial. The Lancet, 397 (10282). pp. 1351-1362. ISSN 0140-6736

Voysey, M, Costa Clemens, SA, Madhi, SA et al. (763 more authors) (2021) Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet, 397 (10277). pp. 881-891. ISSN 0140-6736

Voysey, M, Clemens, SAC, Madhi, SA et al. (80 more authors) (2020) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet, 397 (10269). pp. 99-111. ISSN 0140-6736